Actively Recruiting
Pilot Study of Genotype-Guided Clopidogrel Monotherapy for Adults with Non-ST-Segment Elevation Acute Coronary Syndrome After Successful PCI
Led by St. Antonius Hospital · Updated on 2024-12-03
200
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients with Non-ST-Segment Elevation Acute Coronary Syndrome NSTE-ACS who have successfully undergone Percutaneous Coronary Intervention PCI. The study aims to determine if this genotype-guided treatment reduces ischemic risk and bleeding complications during the first six months after PCI compared to traditional Dual Antiplatelet Therapy DAPT. The focus is on patients who are extensive or ultra-rapid metabolizers of CYP2C19. Participants will receive clopidogrel monotherapy tailored to their CYP2C19 genotype, starting with a loading dose of 300-600 mg orally, followed by a daily maintenance dose of 75 mg for at least six months. This approach is being studied as an alternative to DAPT, which includes aspirin and a P2Y12 inhibitor but is associated with bleeding risks. The intervention is given after successful PCI with new generation drug-eluting stents. During the study, participants will be monitored closely for ischemic events like myocardial infarction, stent thrombosis, and stroke, as well as bleeding events over six months. Assessments include safety and efficacy endpoints at 3 and 6 months, with additional monitoring of mortality and bleeding complications. The trial lasts six months, focusing on the balance between protection from ischemic events and reducing bleeding risk.
CONDITIONS
Brief Title
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
Research Team
J
Jaouad Azzahhafi, MD
J
Jurrien ten Berg, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here